88IV - PR Newswire Asia's news - Biotechnology

< Previous page

| Title only | Print

Next page >

/C O R R E C T I O N -- Ranok Therapeutics/ In the news release, Ranok Therapeutics Announces Positive Interim Phase 1 Data Of Its KRAS G12D Inhibitor RNK08954 In Patients With KRAS G12D-Mutated Metastatic Non-Small Cell Lung Cancer Presented At ... 2026-06-01T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Biond Biologics and Guangzhou-Israel Biotechnology Fund ("GIBF") Announce Closing of $8 Million Investment and Collaboration Biond Biologics and Guangzhou-Israel Biotechnology Fund (GIBF) Announce Strategic Investment and Joint Venture to Advance First-in-Class Oncology Programs in China ... 2026-06-01T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Driving Innovation, Empowering Partners: ACROBiosystems Showcases Comprehensive CGT Solutions Anchored by GMP Capabilities at Bio Korea 2026 SEOUL, South Korea , June 1, 2026 /PRNewswire/ -- ACROBiosystems, a biotechnology company positioning itself as a cornerstone of the global biopharmaceutical and healthcare industries, participated in ... 2026-06-01T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Hanmi Signs Licensing Deal with Lilly for sonefpeglutide (LAPSGLP-2 analog) Lilly licenses Hanmi's sonefpeglutide (LAPSGLP-2 analog) for multiple indications ... 2026-06-01T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
ASCO 2026 \| Oricell's GPC3 CAR-T Ori-C101 Hits 66.7% ORR in Late-Line HCC, Signaling Best-in-Class Potential CHICAGO , June 1, 2026 /PRNewswire/ -- Oricell Therapeutics, a clinical-stage biotech company pioneering cancer immunotherapy, today announced that its lead asset, Ori-C101, a GPC3-targeted CAR-T ... 2026-06-01T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Long-term Follow-up Results of CARsgen's Satri-cel as Sequential Therapy After First-Line Treatment for Gastric Cancer Presented at the 2026 ASCO Annual Meeting SHANGHAI , June 1, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that the long-term analysis ... 2026-06-01T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Lynk Pharmaceuticals Announces NMPA Approval of LNK01004 Ointment's Phase II Clinical Trial for the Treatment of Vitiligo and Chronic Hand Eczema HANGZHOU, China, SHANGHAI and BOSTON , June 1, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on ... 2026-06-01T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
ImmVira Reports 100% Complete Response Rate at 9 Months in Bladder Carcinoma in Situ with MVR-T3011 at ASCO SUZHOU, China , June 1, 2026 /PRNewswire/ -- ImmVira Group ("ImmVira") today announced that preliminary Phase IIa clinical data for MVR-T3011, its lead oncolytic immunotherapy candidate, was ... 2026-06-01T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Jyong Biotech CEO Outlines FDA Pathway and Global Strategy in PharmaBoardroom Live Interview TAIPEI , June 1, 2026 /PRNewswire/ -- Jyong Biotech Ltd. (Nasdaq: MENS) (the "Company" or "Jyong Biotech"), a science-driven biotechnology company dedicated to the development and ... 2026-06-01T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
D3 Bio Presents First-Line Data for Elisrasib (D3S-001) at ASCO 2026; Next-Generation KRAS G12C Inhibitor Shows Landmark Efficacy in Untreated NSCLC Elisrasib monotherapy delivers an ORR of 78.0% and median PFS of 12.4 months in first-line KRAS G12C–mutant NSCLC (n=41) across all PD-L1 expression levels ... 2026-06-01T Biotechnology Health Care/Hospital Medical/Pharmaceuticals

< Previous page

Next page >

88iv | Home | Login

Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer

Copyright (C) 2026

Suntek Computer Systems Limited.

All rights reserved